The National Institute for Health and Clinical Excellence (NICE) published its final appraisal determination on pemetrexed disodium (Alimta) for mesothelioma on 26 June. Consultees were given until 10 July to lodge an appeal against NICE’s determination. NICE will not issue final guidance to the NHS until any appeals have been heard.